New vaccine trial aims to train immune system against leukemia after transplant
NCT ID NCT03679650
First seen Jan 31, 2026 · Last updated Jun 13, 2026 · Updated 17 times
Summary
This early-phase study tests a custom-made cancer vaccine (DC/AML fusion vaccine) for people with acute myeloid leukemia (AML) who have recently had a stem cell transplant. The vaccine is designed to teach the body's immune cells to recognize and attack remaining leukemia cells. Some participants also receive a low-dose chemotherapy drug (decitabine) to boost the vaccine's effect. The goal is to see if the vaccine is safe and can increase leukemia-fighting immune cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.